MALVERN, PA, January 23, 2015 – Alexar Therapeutics, Inc. announced today that it has been awarded a preclinical research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to develop Liver X Receptor (LXR) agonists for the treatment of Parkinson’s disease. The grant will be applied to the discovery of LXR agonists that target specific inflammatory and neurodegenerative pathways in the brain that have been linked to Parkinson’s disease without significant peripheral side effects. This is Alexar Therapeutics’ first grant from MJFF.
“We are honored by the support of MJFF in our efforts to identify a safe and effective LXR-based therapeutic for the treatment of Parkinson’s disease,” said Raju Mohan, PhD, Executive VP of Research at Alexar Therapeutics and Principal Investigator on the grant. “Inflammation is an early and characteristic feature of Parkinson’s disease, and our research approach is based on recent studies that connect the LXR pathways to both inflammation and lipid balance in key tissues in the brain, potentially offering a disease-modifying therapy for this debilitating disease.”
“The greatest unmet need for patients is a therapy that can impact the underlying pathology and slow or prevent progression,” said Marco Baptista, PhD, MJFF Associate Director of research programs. “LXR agonists offer a promising approach toward reaching that goal, and the Foundation is proud to support this project by Alexar Therapeutics.”
As the world’s largest nonprofit funder of Parkinson’s research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson’s disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson’s patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding more than $450 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson’s research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson’s disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson’s awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world.
Alexar Therapeutics is a biopharmaceutical company that is developing topical and systemic therapies based on Liver X Receptor (LXR) modulators. Ralexar’s novel approach focuses on identifying tissue-selective drug candidates that provide broad therapeutic safety. Alexar is currently developing ALX-101, a topical LXR-based therapy, for the treatment of various cutaneous inflammatory disorders.
Mike Beyer, Sam Brown, Inc.